Document Detail


Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
MedLine Citation:
PMID:  22863328     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Many patients with venous leg ulcers do not heal with standard care. HP802-247 is a novel spray-applied cell therapy containing growth-arrested allogeneic neonatal keratinocytes and fibroblasts. We compared different cell concentrations and dosing frequencies of HP802-247 for benefit and harm when applied to chronic venous leg ulcers.
METHODS: We enrolled adult outpatients from 28 centres in the USA and Canada with up to three ulcers, venous reflux confirmed by doppler ultrasonography, and adequate arterial flow in this phase 2, double-blind, randomised, placebo-controlled trial if at least one ulcer measured 2-12 cm(2) in area and had persisted for 6-104 weeks. Patients were randomly assigned by computer-generated block randomisation in a 1:1:1:1:1 ratio to 5·0×10(6) cells per mL every 7 days or every 14 days, or 0·5×10(6) cells per mL every 7 days or every 14 days, or to vehicle alone every 7 days. All five groups received four-layer compression bandages. The trial sponsor, trial monitors, statisticians, investigators, centre personnel, and patients were masked to treatment allocation. The primary endpoint was mean percentage change in wound area at the end of 12 weeks. Analyses were by intention to treat, excluding one patient who died of unrelated causes before first treatment. This trial is registered with ClinicalTrials.gov NCT00852995.
FINDINGS: 45 patients were assigned to 5·0×10(6) cells per mL every 7 days, 44 to 5·0×10(6) cells per mL every 14 days, 43 to 0·5 ×10(6) cells per mL every 7 days, 46 to 0·5 ×10(6) cells per mL every 14 days, and 50 to vehicle alone. All required visits were completed by 205 patients. The primary outcome analysis showed significantly greater mean reduction in wound area associated with active treatment compared with vehicle (p=0·0446), with the dose of 0·5 ×10(6) cells/mL every 14 days showing the largest improvement compared with vehicle (15·98%, 95% CI 5·56-26·41, p=0·0028). Adverse events were much the same across all groups, with only new skin ulcers and cellulitis occurring in more than 5% of patients.
INTERPRETATION: Venous leg ulcers can be healed with a spray formulation of allogeneic neonatal keratinocytes and fibroblasts without the need for tissue engineering, at an optimum dose of 0·5×10(6) cells per mL every 14 days.
FUNDING: Healthpoint Biotherapeutics.
Authors:
Robert S Kirsner; William A Marston; Robert J Snyder; Tommy D Lee; D Innes Cargill; Herbert B Slade
Related Documents :
20824828 - Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionat...
900158 - Case report: chronic disseminated intravascular coagulation due to occult carcinoma.
17292948 - Dose-escalation study of rivaroxaban (bay 59-7939)--an oral, direct factor xa inhibitor...
3047668 - The treatment of venous thromboembolism.
20837368 - Novel non-invasive p wave analysis for the prediction of paroxysmal atrial fibrillation...
23322888 - Absence of airway secretion accumulation predicts tolerance to noninvasive ventilation ...
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-08-03
Journal Detail:
Title:  Lancet     Volume:  380     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-17     Completed Date:  2012-10-03     Revised Date:  2013-02-04    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  977-85     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Dermatology and Cutaneous Surgery, University of Miami, Leonard M Miller School of Medicine, Miami, FL, USA.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00852995
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Double-Blind Method
Female
Fibroblasts / transplantation*
Humans
Infant, Newborn
Keratinocytes / transplantation*
Male
Middle Aged
Treatment Outcome
Varicose Ulcer / pathology,  physiopathology,  therapy*
Wound Healing
Comments/Corrections
Comment In:
Lancet. 2012 Sep 15;380(9846):953-5   [PMID:  22863327 ]
Lancet. 2013 Feb 2;381(9864):372   [PMID:  23374472 ]
Lancet. 2013 Feb 2;381(9864):372   [PMID:  23374474 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological coh...
Next Document:  Control and inhibition analysis of complex formation processes.